0.1750GBp-14.63%Mkt Cap: 4.44M GBpP/E: —Last update: 2026-05-13
Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. The compan…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
P/B—
P/S—
EV/EBITDA-5.21
EV/Revenue—
EPS (TTM)0.00
EPS (Forward)—
Cash Flow & Leverage
FCF Yield-8.45%
FCF Margin—
Operating CF-614.61K GBp
CapEx (TTM)—
Net Debt/EBITDA0.15
Net Debt-97.55K GBp
Technical
SMA 500.1865 (-6.2%)
SMA 2000.2198 (-20.4%)
Beta1.50
S&P 52W Chg24.23%
Avg Vol (30d)22.40M
Avg Vol (10d)26.19M
Technical Indicators
RSI (14)47.0
MACD-0.0031
MACD Signal-0.0057
MACD Hist.+0.0026
BB Upper0.1994 GBp
BB Middle0.1782 GBp
BB Lower0.1570 GBp
BB Width23.77%
ATR (14)0.0295 GBp
Vol Ratio (20d)0.38x
52W Range
0.070022% of range0.5550
52W High0.5550 GBp
52W Low0.0700 GBp
Profitability
Gross Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
Oper. Margin0.00%
ROE-86.44%
ROA-64.05%
Revenue Growth—
Earnings Growth—
Balance Sheet
Debt/Equity—
Current Ratio0.52
Quick Ratio0.43
Book Value/Sh0.0000 GBp
Cash/Share0.0000 GBp
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 GBp
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.2.61B
Float1.92B
Insiders5.37%
Institutions0.07%
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Company
Market Cap4.44M GBp
Enterprise Value3.30M GBp
Revenue (TTM)—
Gross Profit0 GBp
Net Income (TTM)-652.59K GBp
Revenue/Share—
Fiscal Year EndSep 2025
MR QuarterSep 2025
Employees3
Last Price0.1750 GBp
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—